EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access · CC BY-NC 4.0

Barriers to accessing hepatitis B medication: a qualitative study from the USA and Canada

Michaela Jackson iD, Yasmin Ibrahim, Catherine Freeland, Sophie Jacob, Beatrice Zovich, Chari Cohen

BMJ Open · 2024

DOI: 10.1136/bmjopen-2023-080658 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift BMJ Open, 2024. Verfasst von Michaela Jackson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hepatitis B Foundation, Doylestown, Pennsylvania, USA michaela.jackson@hepb.org. Hauptthemen laut MEDLINE: Qualitative Research, Health Services Accessibility, Antiviral Agents, Hepatitis B. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To collect and document the numerous barriers that people living with hepatitis B (PLHB) encounter when trying to access their hepatitis B virus (HBV) medications.

Design

Researchers collected qualitative data through 24 online interviews. The semistructured interview questions focused on the impact that HBV has on different aspects of daily life (physical, emotional and social), personal experiences managing their infection, HBV treatment experiences and interactions with healthcare providers.

Setting

All interviews occurred over Zoom.

Participants

The participant cohort consisted of 12 males and 12 females. 63% of all participants represented communities of colour (37% white, 17% black/African/African American and 46% Asian/Asian American). Most of the participants were on antiviral treatment at the time of the study (62%). Participants were PLHB (self-reported), ≥18 years old, living in the USA or Canada and spoke English.

Results

Participants reported several barriers to accessing medicine among PLHB including financial barriers, health insurance and pharmacy preauthorisation process and other intangible barriers like lack of access to reliable patient-friendly information and stigma. The identified barriers to accessing HBV medication impacted patients’ continuity of care.

Conclusions

Access to medicine is essential to improving health outcomes. PLHB experience significant barriers to accessing HBV antivirals at different levels. Patient-related, physician-related and healthcare system barriers were identified as themes contributing to antiviral access challenges. More research is needed to identify strategies to improve access to HBV medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Qualitative ResearchHealth Services AccessibilityAntiviral AgentsHepatitis BHumansMaleFemaleAdultUnited StatesCanadaMiddle AgedSocial StigmaYoung AdultHepatitis B, ChronicInterviews as TopicAged

Stichwörter der Autor:innen

chronic diseaseinfectious diseasesmedication adherencequalitative researchquality of life

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Hepatitis B Foundation, Doylestown, Pennsylvania, USA michaela.jackson@hepb.org.
  • Hepatitis B Foundation, Doylestown, Pennsylvania, USA.

ORCID-Profile: Michaela Jackson

Zitieren

APA

Jackson, M., Ibrahim, Y., Freeland, C., Jacob, S., Zovich, B., & Cohen, C. (2024). Barriers to accessing hepatitis B medication: a qualitative study from the USA and Canada. BMJ Open. https://doi.org/10.1136/bmjopen-2023-080658

Vancouver

Jackson M, Ibrahim Y, Freeland C, Jacob S, Zovich B, Cohen C. Barriers to accessing hepatitis B medication: a qualitative study from the USA and Canada. BMJ Open. 2024. doi:10.1136/bmjopen-2023-080658

BibTeX
@article{Jackson2024,
  author = {Jackson, Michaela and Ibrahim, Yasmin and Freeland, Catherine and Jacob, Sophie and Zovich, Beatrice and Cohen, Chari},
  title = {Barriers to accessing hepatitis B medication: a qualitative study from the USA and Canada},
  journal = {BMJ Open},
  year = {2024},
  doi = {10.1136/bmjopen-2023-080658}
}
Kostenlos starten →